Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, James Chih-Hsin Yang, Pan-Chyr Yang, Jin-Yuan Shih. J Thorac Oncol 2016
Times Cited: 50
Times Cited: 50
Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, Dae Seog Heo. Clin Cancer Res 2015
Times Cited: 94
Times Cited: 94
List of shared articles
Times cited
ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Francesco Facchinetti, Giulio Rossi, Emilio Bria, Jean-Charles Soria, Benjamin Besse, Roberta Minari, Luc Friboulet, Marcello Tiseo. Cancer Treat Rev 2017
Francesco Facchinetti, Giulio Rossi, Emilio Bria, Jean-Charles Soria, Benjamin Besse, Roberta Minari, Luc Friboulet, Marcello Tiseo. Cancer Treat Rev 2017
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo. Cancer Chemother Pharmacol 2019
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo. Cancer Chemother Pharmacol 2019
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
ROS1-rearranged Non-small Cell Lung Cancer.
Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.
Kartik Sehgal, Rushad Patell, Deepa Rangachari, Daniel B Costa. Transl Cancer Res 2018
Kartik Sehgal, Rushad Patell, Deepa Rangachari, Daniel B Costa. Transl Cancer Res 2018
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.
Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda,[...]. J Thorac Dis 2019
Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda,[...]. J Thorac Dis 2019